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ABSTRACT:
The pharmacokinetics of daikenchuto (TJ-100), a pharmaceutical-
grade traditional Japanese medicine, were investigated in healthy
Japanese volunteers after a single oral administration of 2.5-, 5-,
and 10-g doses. Six ingredients [hydroxy--sanshool (HAS), hy-
droxy--sanshool (HBS), [6]-shogaol (6S), [10]-shogaol (10S), gin-
senoside Rb1(GRB1), and ginsenoside Rg1(GRG1)] of TJ-100 were
determined by using liquid chromatography-tandem mass spec-
trometry. The results indicated that HAS, an ingredient derived
from Zanthoxylum piperitum fruit, exhibited the highest plasma
concentration among the six ingredients investigated. The plasma con-
centrations of HAS, HBS, 6S, and 10S reached the maximum con-
centration (approximately 400, 80, 0.14, and 0.6 ng/ml, respectively,
after a 5-g administration of TJ-100) within 30 min after adminis-
tration, and the mean half-life was approximately 2 h. Thus, these
compounds were rapidly absorbed and eliminated. The plasma
concentration of GRB1 reached the maximum concentration (2
ng/ml after a 5-g administration of TJ-100) at approximately 4 h
after administration and the half-life of GRB1 was approximately
40 h. The plasma concentration of GRG1 was extremely low
(<0.023 ng/ml). The pharmacokinetics of HAS, HBS, 6S, and 10S,
were linear within the range of 2.5 to 10 g/day of TJ-100. On the
other hand, the kinetics of GRB1 and GRG1 were not proportional
to dosage, and plateauing was observed.
Introduction
Daikenchuto (TJ-100) is a pharmaceutical-grade traditional Jap-
anese medicine consisting of Japanese pepper (Zanthoxylum spp.
fruit), processed ginger, and ginseng with maltose as an additive.
In Japan, TJ-100 is routinely used in the modern medical care
system as a prescription drug for the treatment of various gastro-
intestinal disorders, including postoperative ileus, postoperative
intestinal paralysis, and adhesive bowel obstructions (Itoh et al.,
2002; Kono et al., 2009). Results from a recent clinical pharma-
cological study have shown that TJ-100 accelerates intestinal tran-
sit in healthy humans (Manabe et al., 2010). Furthermore, basic
pharmacological studies have suggested that TJ-100 and its ingre-
dients have a wide variety of biological effects, including a pro-
kinetic effect largely attributed to the activity of Zanthoxylum
piperitum fruit (Jin et al., 2001; Kawasaki et al., 2007; Tokita et
al., 2007a,b), contraction and relaxation of intestinal smooth mus-
cle (Kito and Suzuki, 2006), an increase in intestinal blood flow
due to the activity of ginger ingredients (Murata et al., 2002; Kono
et al., 2008), an anti-inflammatory effect (Kono et al., 2010), and
suppression of bacterial translocation possibly mediated by gin-
seng ingredients (Yoshikawa et al., 2008).
Estimating the factors involved in the absorption, distribution,
metabolism, and excretion of the multiple constituents in a Kampo
medicine is an ongoing challenge, and obtaining a consistent picture
of its mechanism of action is difficult as well. To solve these prob-
lems, we have conducted preliminary clinical trials to obtain the
profiles of compounds absorbed in the plasma and urine after a single
oral administration of 15 g of TJ-100 in four healthy volunteers
(Iwabu et al., 2010). In that study, we constructed a liquid chroma-
tography-tandem mass spectrometry analysis to detect as many com-
pounds as possible and successfully identified 44 ingredients of TJ-
100. Twenty-three ingredients and their metabolites were detected in
the plasma, indicating that a large number of TJ-100 ingredients were
actually absorbed and metabolized.
On the basis of the results, we have developed assay methods for
six compounds, hydroxy--sanshool, hydroxyl--sanshool, [6]-shogaol,
[10]-shogaol, ginsenoside Rb1, and ginsenoside Rg1, using the following
criteria: 1) plasma concentrations of the compounds have enough strength
to establish the validated determination methods; 2) the measurement at
least one compound per botanical raw material is enabled; and 3) phar-
macological activities of the selected compounds have been reported
previously. In this study, we focused on the pharmacokinetics of the
ingredients of TJ-100.
Materials and Methods
Chemicals and Reagents. Tsumura Daikenchuto Extract Granules was
manufactured by Tsumura & Co. (Ami, Ibaraki, Japan). Fifteen grams of
Tsumura Daikenchuto Extract Granules contains 1.25 g of a dried extract
prepared from a mixture of three herbs (5.0 g of processed ginger, 3.0 g of
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ginseng, and 2.0 g of Japanese pepper) and 10.0 g of maltose. Extra pure-grade
acetonitrile and high-performance liquid chromatography-grade acetic acid
were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Asiaticoside was purchased from Extrasynthese (Genay, France), and noniv-
amide was from Enzo Life Sciences, Inc. (Farmingdale, NY). Water was
purified using a pure water supply system (Milli-Q, Nihon Millipore Ltd.,
Tokyo, Japan). An Oasis HLB Elution Plate (Nihon Waters K.K, Tokyo,
Japan) was used as the solid-phase extraction plate. The isolation, synthesis,
and identification of the six authentic standards of the TJ-100 ingredients were
described in a previous article (Iwabu et al., 2010). The structural formulas of
the authentic standards are provided in Supplemental Fig. 1.
Clinical Trial Design, Administration, and Sample Collection. This was
a randomized, open-label, three-arm, three-period study (Japic CTI-101114)
conducted at the Kochi Medical School. Nineteen subjects participated in this
study, but three subjects were excluded from the pharmacokinetic analysis
because they did not meet the eligibility criteria. The safety endpoint was
evaluated in 19 subjects. Participants fasted from 12 h before and 4 h after
administration. All foods and drinks (including spices) containing ginseng,
Japanese pepper, and ginger were strictly prohibited for 3 days before dispens-
ing of the study medication until completion of each treatment phase. Blood
samples (7 ml each) were collected from the medial cubital vein into evacuated
tubes containing heparin just before and at 0.25, 0.5, 1, 2, 3, 4, 8, 12, 24, and
48 h after administration and were immediately centrifuged (1700g, 10 min).
Plasma fractions were stored at 20°C until analysis. All study procedures
were conducted in accordance with the ethical principles of the Declaration of
Helsinki, consistent with Good Clinical Practice guidelines, and approved by
the institutional review board at Kochi Medical School Hospital. Subjects gave
their written informed consent before participating in the study.
Determination of Plasma Concentrations of TJ-100 Ingredients. The
concentrations of six TJ-100 ingredients were determined according to the
method reported by Iwabu et al. (2010) with modification. In brief, 200 l of
the plasma samples were mixed with 200 l of 0.1 M hydrochloric acid, 10 l
of internal standard solution (schizandrin: 10 ng/ml for HAS and HBS;
nonivamide: 10 ng/ml for 6S and 10S; and asiaticoside: 100 ng/ml for GRB1
and GRG1) and 10 l of water-acetonitrile [7:3 (v/v)]. The resulting mixture
was loaded onto an Oasis HLB Elution 96-well plate (30 m), which was
washed with 200 l of methanol and 200 l of water. The plate was then
washed with 200 l of water and eluted with 50 l of acetonitrile. A 40-l
portion of the eluate was mixed with 60 l of water, and a 20-l portion was
injected into the Agilent 1200 series high-performance liquid chromatography
system (Agilent Technologies, Santa Clara, CA) with a Sciex API 5000 (AB
SCIEX, Tokyo, Japan). A YMC-Pack ODA-AQ column (3 m, 150  2.0 mm
i.d.; YMC Co., Ltd., Kyoto, Japan) was used for analyzing HAS, HBS, GRB1,
and GRG1; a YMC-Pack ODA-AQ column (3 m, 50  2.0 mm i.d., YMC
Co., Ltd.) was used for analyzing 6S and 10S. The analytical methods were
validated according to the U.S. Food and Drug Administration Guidance for
Industry Bioanalytical Method Validation (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf). These ana-
FIG. 1. A semilogarithmic plot of plasma con-
centrations of main TJ-100 ingredients in hu-
man healthy volunteers. The results of quanti-
fication of main TJ-100 ingredients in human
plasma are shown. A, HAS. B, HBS. C, 6S. D,
10S. E, GRB1. F, GRG1. F, 2.5 g; f, 5 g; Œ,
10 g. Values are means of the results  S.D.
n  15 or 16.
1785PHARMACOKINETICS STUDY OF DAIKENCHUTO
lytical methods and their validation data are summarized in Supplemental Tables 1, 2,
and 3.
Pharmacokinetic Analysis. Pharmacokinetic parameters were estimated
using WinNonlin (version 5.2; Pharsight, Mountain View, CA). Experimen-
tally observed values of maximum concentration (Cmax) and time to maximum
concentration (tmax) after TJ-100 administration were used for the analysis.
The area under the plasma concentration-time curve from zero to time t
(AUC0–last) was calculated from time 0 to the last detected time. Apparent
elimination half-life (t1/2) was calculated divided by loge2/ke where ke is the
terminal elimination rate constant. Cmax and AUC0–last are presented as the
mean  S.D. The apparent elimination half-life and tmax are presented as
the median with range.
Evaluation of Linearity of Dosage-Exposure Relations. The dose pro-
portionality was analyzed via a power model fitted as a linear mixed-effects
model that included the period effect and random subject effect (eq. 1):
ln(PK)ijk  0  1 ln(Doseij)  j  ak  ijk (1)
ln(PK)ijk is the natural logarithm of the AUC0–last or Cmax in group i (i 
A, B, C) during period j (j  1, 2, 3) in the subject (k  1, 2, . . . , ni). The
Doseij is the administered dose (g) of the test drug in group i during period j.
j is the term to express the fixed period effect, and ak is the term to express
the subject-specific effect, which is assumed to be normally distributed around
mean 0 with intersubject S.D. of a. ijk is the error term with mean 0 and S.D.
. 1 is the parameter to be used for the dose proportionality evaluation, and
0 is the intercept term. When the value of 1 differs significantly from 1, the
hypothesis of dose proportionality is rejected. Evaluation of linearity of the
dosage-exposure relations analysis was conducted using SAS 9.1.3 (SAS
Institute, Inc., Cary, NC).
Results and Discussion
Study Subjects and Adverse Effects. Sixteen healthy subjects
(age, 20–37 years; height, 150.7–189.7 cm; weight, 44.5–72.5 kg; and
body mass index, 18.5–24.1 kg/m2) were included in the pharmaco-
kinetic analysis in this study. There was an uneven gender ratio in the
study (13 men and 3 women). Six adverse experiences were observed
in four patients, all of which were deviations from normal reference
laboratory values. However, these deviations were judged by the
principal investigator to be physiological changes; thus, a causal
relationship with TJ-100 was denied.
Pharmacokinetics in Human Subjects. The plasma concentra-
tion-time profiles in the human subjects for each dose (2.5, 5, and
10 g) are shown in Fig. 1. The pharmacokinetic parameters of the six
main TJ-100 ingredients are summarized in Table 1.
HAS, which is a constituent of Z. piperitum fruit, exhibited the
highest plasma concentration among the six compounds measured.
The plasma concentration of HAS reached the maximum concentra-
tion within 30 min after administration and its median half-life was
1.6 to 1.7 h, indicating its rapid absorption and elimination. The
plasma concentration of HBS showed a pattern parallel to the plasma
concentration of the HAS. It has been reported that both HAS and
HBS have unique biological activities and play an important role in
the efficacy of TJ-100 (Hayakawa et al., 1999; Tokita et al., 2007a,b).
Various in vitro experimental systems have demonstrated that HAS
exerts its pharmacological effects in the range of 0.1 to 100 M (Jin
et al., 2001; Koo et al., 2007). In this study, the maximum concen-
tration of HAS in plasma was 0.76 to 2.66 M. Taken together, these
results suggest that HAS absorption into the blood circulation may
contribute to the pharmacological effects of orally administered TJ-
100. These findings are intriguing in light of the fact that several
studies strongly suggest a localized effect of TJ-100; that is, TJ-100
ingredients mainly affect the mucosal, nervous, and smooth muscle
cells in the intestinal lumen. For example, intraduodenal and intraje-
junal TJ-100 administration induced phasic contractions in the duo-
denum and proximal jejunum, respectively, and those contractions
migrated distally (Shibata et al., 1999; Jin et al., 2001). No motor
response was obtained proximal to the site of administration, suggest-
ing that direct contact with the intestinal mucosa is essential for
TJ-100 to exert its effects. The results of this pharmacokinetic study
TABLE 1
Pharmacokinetic parameters for components of TJ-100
Data represent the mean  S.D. or median (range).
Dose n AUC0–last Cmax t1/2 tmax
ng  h/ml ng/ml h h
HAS
2.5 g/day 15 349  136 209  100 1.65 (1.01–2.48) 0.250 (0.229–1.00)
5 g/day 16 658  223 391  136 1.71 (1.04–3.26) 0.258 (0.233–0.633)
10 g/day 16 1290  329 664  165 1.62 (1.46–3.22) 0.475 (0.233–0.550)
HBS
2.5 g/day 15 66.3  35.0 42.2  25.5 1.14 (0.478–1.71) 0.267 (0.229–1.00)
5 g/day 16 130  81.4 80.4  45.9 1.17 (0.681–1.76) 0.258 (0.233–0.633)
10 g/day 16 234  88.4 131  52.6 1.09 (0.925–1.70) 0.475 (0.233–0.550)
6Sa
2.5 g/day 15 0.0306  0.0211 0.0762  0.0542 0.618 (0.280–0.956) 0.233 (0.229–0.550)
5 g/day 16 0.0751  0.0571 0.142  0.109 0.312 (0.286–0.793) 0.242 (0.233–0.500)
10 g/day 16 0.173  0.0907 0.262  0.125 0.429 (0.302–0.526) 0.250 (0.233–0.533)
10Sb
2.5 g/day 15 0.397  0.372 0.290  0.157 1.46 (0.463–4.66) 0.500 (0.229–0.983)
5 g/day 16 0.821  0.522 0.636  0.341 0.851 (0.559–3.45) 0.317 (0.233–3.00)
10 g/day 16 1.48  0.760 1.20  0.742 0.812 (0.460–5.42) 0.483 (0.233–1.90)
GRB1
2.5 g/day 15 1.33  0.653 0.0504  0.0189 37.8 (12.2–101) 4.00 (2.98–8.00)
5 g/day 16 2.27  0.839 0.0744  0.0229 41.0 (21.3–330) 4.02 (1.98–12.0)
10 g/day 16 3.45  1.39 0.123  0.0466 40.1 (20.3–5398) 3.98 (2.92–7.98)
GRG1c
2.5 g/day 15 0.191  0.241 0.0198  0.0320 27.8 (2.07–53.5) 2.48 (0.500–8.00)
5 g/day 16 0.209  0.236 0.0209  0.00910 4.40 (2.06–1390) 1.00 (0.233–3.93)
10 g/day 16 0.113  0.0802 0.0230  0.0117 14.3 (2.69–171) 1.96 (0.983–23.7)
a The elimination half-life was calculated from 2 subjects at the dose of 2.5 g, 10 subjects at the dose of 5 g, and 12 subjects at the dose of 10 g.
b The elimination half-life was calculated from 10 subjects at the dose of 2.5 g, 15 subjects at the dose of 5 g, and 16 subjects at the dose of 10 g.
c The elimination half-life was calculated from 2 subjects at the dose of 2.5 g, 3 subjects at the dose of 5 g, and 7 subjects at the dose of 10 g.
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underscore the importance of clarifying whether HAS has systemic
biological effects.
The plasma concentrations of 6S and 10S, the constituents of
processed ginger, were significantly lower than those of Z. piperitum
fruit constituents. The values of Cmax of 6S were observed within 15
min after administration, and its elimination half-life was 0.3 to 0.6 h.
Meanwhile, 10S reached maximum plasma concentrations within 30
min after administration, and its elimination rate was slightly lower
than that of 6S at 0.8 to 1.5 h. Although the plasma concentrations of
6S and 10S were extremely low, it is possible that their intestinal
concentrations were sufficient to exert an effect in the intestinal
lumen.
Conversely, the plasma concentration of GRB1, which is one of the
constituents of ginseng, gradually increased, with a tmax of approxi-
mately 4 h followed by maximum plasma concentrations. Thereafter,
GRB1 was gradually eliminated with a half-life of approximately
40 h. The tmax and the half-life of GRB1 indicate a relatively slow
increase and gradual disappearance. The plasma concentrations of
GRB1 are therefore expected to increase to levels higher than the
concentrations observed in this study when TJ-100 is administered
repeatedly. From the present data, we anticipate that five half-lives
can be measured once a steady-state blood concentration of GRB1 is
achieved after approximately 1 to 2 weeks of repeated administration.
Although there are a few adverse reports related to the long-term use
of TJ-100 in Japan, repeated-dose pharmacokinetic trials will be
required to clarify this point. In addition, the information on plasma
concentration of GRB1 after repeated TJ-100 is useful to discuss the
possible involvement of the ingredient in the clinical effect of TJ-100.
Calculation of the elimination half-life of GRG1 was possible in only
a few subjects because the plasma concentration of GRG1 was low
and less than the lower limit of quantitation (0.01 ng/ml) in many of
the subjects.
Analysis of Linearity in Dosage-Exposure Relations. The dose
proportionality of AUC0–last is graphically displayed in Fig. 2. The 1
of HAS, HBS, 6S, and 10S for AUC0–last was close to 1 for doses
ranging between 2.5 and 10 g of TJ-100. These results suggested that
the pharmacokinetics of HAS, HBS, 6S, and 10S were linear within
the dose range of 2.5 to 10 g/day of TJ-100. However, a 90%
confidence interval of the 1 value for GRB1 did not include 1.
Whereas the AUC0–last value of GRB1 was very limited because the
last observation time points were only 50% of the estimated half-life,
the result inferred a plateauing phenomenon of GRB1. The analysis
for GRG1 was not conducted because only a few subjects had detect-
able plasma concentrations. The result of dose proportionality for
Cmax was similar to that of AUC0–last. The present study provides a
strong basis for future absorption, distribution, metabolism, and ex-
cretion studies to help create a consistent kinetic profile and to
generate robust evidence on the pharmacological activity of TJ-100.
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